LEUPROLIDE ACETATE FOR DEPOT SUSPENSION: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Invagen Pharms	LEUPROLIDE ACETATE FOR DEPOT SUSPENSION	leuprolide acetate	FOR SUSPENSION;INTRAMUSCULAR	205054	NDA	CIPLA USA INC.	69097-909-50	1 KIT in 1 CARTON (69097-909-50) * 2 mL in 1 VIAL, SINGLE-DOSE (69097-950-32) * 2 mL in 1 SYRINGE (69097-960-31)	2022-07-15
Invagen Pharms	LEUPROLIDE ACETATE FOR DEPOT SUSPENSION	leuprolide acetate	FOR SUSPENSION;INTRAMUSCULAR	205054	NDA	Avyxa Pharma, LLC	83831-134-01	1 KIT in 1 CARTON (83831-134-01) * 2 mL in 1 VIAL, SINGLE-DOSE (83831-150-22) * 2 mL in 1 SYRINGE (83831-135-02)	2025-03-26
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

Leuprolide acetate for depot suspension is a long-acting GnRH (gonadotropin-releasing hormone) analog extensively prescribed for hormone-dependent cancers such as prostate cancer, precocious puberty, endometriosis, and uterine fibroids. As a critical component of hormonal therapy, its supply chain encompasses various manufacturers and suppliers spanning multiple regions. Ensuring reliable sourcing of this medication is vital for healthcare providers, pharmaceutical companies, and patients. This report examines key suppliers, manufacturing landscape dynamics, regulatory considerations, and market trends related to leuprolide acetate depot suspension.

Manufacturers and Suppliers of Leuprolide Acetate Depot Suspension

1. Major Pharmaceutical Manufacturers

The global supply of leuprolide acetate depot suspension predominantly relies on a handful of established pharmaceutical companies with extensive manufacturing capabilities:

AbbVie Inc.
Product Portfolio: Marketed under the brand name Lupron Depot, AbbVie is one of the leading developers and suppliers of leuprolide acetate depot formulations.
Manufacturing Footprint: Operates manufacturing facilities in the United States and Europe, ensuring high-quality standards and supply stability.
Market Role: As a pioneer and major provider, AbbVie's products are widely distributed globally, especially within North America and Europe.
Ferring Pharmaceuticals
Product Portfolio: Offers Lupron Depot formulations in certain regions, with a focus on specialist treatments.
Distribution: Active in European markets and certain Asian markets, maintaining a robust supply network for leuprolide acetate depot forms.
Sun Pharmaceutical Industries Ltd.
Product Portfolio: Manufactures and markets generic versions of leuprolide acetate depot suspension, addressing the demand for more affordable options.
Market Reach: Strong presence in India, with expanding distribution in other emerging markets.
Watson Pharmaceuticals (now part of Teva Pharmaceuticals)
Role: Historically, a supplier of generic leuprolide acetate depot formulations, with widespread distribution capabilities.

2. Contract Manufacturing Organizations (CMOs)

Several CMOs serve as outsourcing partners, producing leuprolide acetate depot suspensions under various brand names or for different clients:

Biotech companies in India and Eastern Europe
These regions host numerous pharmaceutical CMOs specializing in hormone formulations, contributing substantially to global supply, especially in generics.
Regulatory and quality considerations:
Many of these CMOs operate under stringent regulations such as WHO GMP, FDA, or EMA standards, ensuring quality compliance for export markets.

Regional Market Dynamics and Supply Chain Considerations

North America and Europe

The market is predominantly governed by branded products from large pharmaceutical firms like AbbVie, with manufacturing concentrated within North America and Europe. Supply chains here benefit from strict regulation and high-quality standards, though they are susceptible to patent protections and patent cliff challenges.

Emerging Markets

India and China emerge as key players in generic and biosimilar manufacturing of leuprolide acetate depot suspension. Indian companies like Sun Pharma and Zydus Cadila leverage local manufacturing advantages, offering cost-effective options aligned with global standards. This diversification enhances supply resilience but raises concerns over quality and regulatory compliance.

Regulatory Impacts on Supply

Regulations by the FDA, EMA, and other agencies influence manufacturing licenses, quality standards, and approval processes. Changes in regulatory policies, biosimilar pathways, or patent litigations can impact global supply stability and pricing.

Supply Chain Risks and Challenges

Manufacturing Complexities:
The complex formulation of depot suspensions necessitates precise manufacturing processes to optimize drug stability and efficacy, which can limit the number of capable suppliers.
Intellectual Property and Patent Issues:
Patent expirations open opportunities for generics but also create potential for legal disputes, impacting supply continuity.
Global Disruptions:
Factors such as geopolitical tensions, trade restrictions, pandemics (e.g., COVID-19), and raw material shortages can disrupt production and distribution.
Quality Assurance:
Ensuring consistent quality across multiple suppliers is essential. Variability in global manufacturing standards can jeopardize supply reliability.

Market Trends and Future Outlook

Growth in Biosimilars and Generics:
Patent expiries of branded formulations have led to an increase in generic suppliers, reducing prices and diversifying supply sources.
Technological Innovations:
Advances in formulation technology may streamline manufacturing, improve stability, and enhance shelf-life, reducing dependency on limited suppliers.
Regional Expansion:
Increased production capacity in emerging markets offers promising growth avenues, potentially stabilizing supply volumes.
Regulatory Harmonization:
Efforts towards global regulatory convergence may facilitate faster approval processes and higher quality standards, ensuring uninterrupted supply.

Key Takeaways

The supply of leuprolide acetate for depot suspension is dominated by a few key global pharmaceutical companies, notably AbbVie and Ferring, with significant contributions from Indian and other emerging market manufacturers.
Contract manufacturing plays a crucial role, especially in the proliferation of generic and biosimilar versions, expanding access but requiring diligent quality oversight.
Geopolitical, regulatory, and manufacturing complexities pose ongoing risks to supply chain stability; diversification across regions and manufacturers mitigates these risks.
Market trends indicate growing availability of generic options, driven by patent expirations and technological enhancements, which improve affordability and access.
Stakeholders must monitor regulatory developments and supply chain disruptions to ensure continuous patient access to this vital therapy.

FAQs

1. Who are the primary global manufacturers of leuprolide acetate depot suspension?
Major players include AbbVie (Lupron Depot), Ferring Pharmaceuticals, and several Indian generic manufacturers such as Sun Pharma and Zydus Cadila. Contract manufacturing organizations also supply formulations for various companies.

2. How does regional regulation influence the supply of leuprolide acetate depot suspension?
Regulatory agencies like the FDA and EMA set strict quality standards. Approval delays, manufacturing violations, or regulatory strictness can affect supply availability and distribution in different regions.

3. What are the main challenges in sourcing leuprolide acetate depot suspension?
Challenges include manufacturing complexities, patent-related legal issues, geopolitical disruptions, and ensuring consistent quality across multiple suppliers.

4. Are biosimilars or generic versions impacting the supply landscape?
Yes. Patent expirations have led to increased production of generic forms, enhancing competition, reducing prices, and improving supply resilience.

5. What future supply chain developments could influence the availability of leuprolide acetate depot suspension?
Innovations in formulation technology, regional manufacturing capacity expansion, and regulatory harmonization are expected to improve supply stability and access.

References

[1] "Leuprolide Acetate for Depot Suspension," Drugs.com, 2023.
[2] AbbVie Corporate Website, “Lupron Depot,” 2023.
[3] "Global Pharmaceutical Contract Manufacturing Market," MarketsandMarkets, 2022.
[4] World Health Organization – WHO GMP guidelines, 2022.
[5] Indian Pharmacopoeia Commission, “Generic Hormonal Products,” 2022.

Suppliers and packagers for LEUPROLIDE ACETATE FOR DEPOT SUSPENSION